1875-Breast trastuzumab subcutaneous

trastuzumab  Key Message The ShortHER trial failed to demonstrate the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy The short In the DESTINY-Breast04 trial, trastuzumab deruxtecan showed superior activity over standard chemotherapy options in patients with HER2-low advanced breast

Descriptions Trastuzumab injection is used to treat HER2-overexpressing new or metastatic breast cancer It can be Trastuzumab has also been shown to penetrate an impaired blood–brain barrier to a limited degree, such as during radiotherapy, and intrathecal delivery of

In 2006, trastuzumab plus chemotherapy was approved to treat patients after their HER2-overexpressing breast tumors were surgically removed  Trastuzumab prolongs survival in metastatic breast cancer patients whose tumors over express HER2 It is effective when given as a single agent or in